Cannabis, marijuana and Hemp stock news from Investorideas.com plus daily cannabis #potcasts - Investor Ideas #Potcasts #Cannabis News and Stocks on the Move
VOD Channel Offers Collection of Content
Covering All Things Cannabis
Los Angeles - April 20, 2017 (Investorideas.com Newswire)
Recognizing the increasing entrenchment of cannabis in the global zeitgeist,
420 Entertainment Group, comprised of OWNZONES Media Network, the upstart
global OTT technology/entertainment hybrid company, along with cannabis
entrepreneurs Genesis Media and Alex Nahai Enterprises (ANE), will launch
420TV, a new video-on-demand channel, hailing the wonders of weed.
420TV will feature original, multi-episodic series, as well as
long- and short-form news, information and entertainment content focusing on
all things cannabis. All content will be shot in 4K.
Hundreds of #Marijuana #Investors Meet Dozens
of Start Ups in Austin, TX May 2-3
Noted Canadian entrepreneur Jim Estill and
Austin-based herbal products pioneer Mark Blumenthal to address the group;
Dozens of Promising Cannabis Companies from Around the World Pitch Investors in
'Shark-Tank' Style Format
Austin, TX - April 20, 2017 (Investorideas.com Newswire) More
than 200 high-net worth investors from around the world, eager to invest in the
fastest growing industry in America will gather at AT&T Conference &
Education Center for a two day "Shark Tank"-like pitch forum on
Tuesday, May 2nd and Wednesday, May 3rd, hosted exclusively for members of The
Arcview Investor Network. A disproportionate number of Arcview's most active
investors reside in Texas and have an opportunity to learn of promising
companies in one the fastest growing entrepreneurial cities in the country.
Arcview is the top source of deal flow for the cannabis
industry. It's members have placed $112M into 141 cannabis-related companies.
Jim Estill, Canadian entrepreneur, investor and CEO of Danby
Appliances, and Mark Blumenthal, founder of the American Botanical Council,
will deliver keynote speeches. Accredited investors will be reviewing pitches
from more than a dozen companies who competed fiercely for the pitch slots out
of a field of hundreds of applicants.
Texas has already passed a law allowing non psychoactive
cannabidiol (CBD) for residents and will soon consider whether to legalize
medical cannabis use.
Who: Members
of The Arcview Investor Network plus cannabis-related companies chosen to
present
What: Select
media representatives will be invited to witness presentations from
companies that have been successful at raising capital from this group and
those who are hoping to attract investors at this meeting. Throughout the
day, select reporters will be able to interview high net worth investors
who have recently invested in the sector or are considering it, companies
that have recently been funded, and elected officials that support legalization.
When:
Tuesday, May 2nd and Wednesday, May 3rd between 9:30AM – 4:00PM
Where:
AT&T Conference Center, 1900 University Avenue, Austin, TX 78705
How: Members
of the media must apply for press credentials by emailing
abbybenjamin@arcviewgroup.com
Learn more about the growth of the cannabis industry via this
short video. To get a sense of what to expect at Arcview, see this other short
video.
About
The Arcview Group
Founded in 2010, The Arcview Group is responsible for a number
of groundbreaking ventures in the cannabis industry. The Arcview Investor
Network includes more than 625 accredited investors who have put more than $112
million behind 141 companies. Arcview Market Research publishes the State of
Legal Marijuana Markets report, which is the most oft-cited market data report.
In 2015 Arcview became a partner in Canopy, the first seed-stage mentor-driven
business accelerator. Arcview is also co-founder of Cannasure Insurance
Services, the leading provider of business insurance to the cannabis industry.
Contact:
Abby Benjamin, Media Relations
abbybenjamin@arcviewgroup.com
720-518-7611
This news is published on the
Investorideas.com Newswire - a global digital news source for investors and
business leaders
Disclaimer/Disclosure:Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
Montel
Williams Debuts Line of Medical Cannabis Products
San Francisco, CA - April 20, 2017
(Investorideas.com Newswire) On Tuesday April 18, 2017, Lenitiv Scientific LLC
debuts its line of high-quality medical cannabis products for patients, under
the brand name LenitivLabs, in dispensaries across California. Alongside the
debut, media personality Montel Williams, founder of Lenitiv Scientific, will
host the following launch events at Bay Area dispensaries:
April 18, 7pm to 9pm, at
Caliva (1695 S 7th St, San Jose, CA 95112)
April 19, 7pm to 9pm, at
Purple Lotus Patient Center (752 Commercial St #20, San Jose, CA 95112)
April 21, 7pm to 9pm, at
Harvest on Geary (4811 Geary Blvd, San Francisco, CA 94118)
LenitivLabs' line of proprietary
products utilize the latest cannabis manufacturing technologies and research to
deliver the highest quality and consistency to patients. The line includes
cannabis oils that patients can conveniently load into vaporizers as well as a
cannabis infused drink. Patients will feel safe knowing there are no harmful
additives and the products are clearly labeled and packaged in consistent,
standardized doses.
"I'm thrilled to be debuting
LenitivLabs," says founder Montel Williams. "My mission—and the
mission of our entire Lenitiv team—is to ensure that patients like myself have
access to the highest-quality medicine available."
Williams—an award-winning media personality,
decorated former Naval officer, entrepreneur, and wellness advocate—was
diagnosed with Multiple Sclerosis (MS) in 1999 and has used cannabis products
as a medication to manage the disease's symptoms.
"Medical cannabis has allowed me
to live a productive, fruitful life despite having multiple sclerosis,"
says Williams. "Many thousands of others across this country have
experienced the same thing, which is what drove me to launch Lenitiv
Scientific."
Williams is one of the nation's
highest-profile advocates for cannabis law reform and has championed the cause
for the past seventeen years. He has worked to pass medical cannabis
legislation in states such as Pennsylvania, New York, Ohio, New Jersey, and
Connecticut and continues to advocate for reform at the federal level and in
states where medical cannabis laws are not currently in effect. An outspoken
advocate for America's servicemen and women, Williams has led the push for
military veterans to legally access medical cannabis without the threat of
losing benefits.
Beginning in April, LenitivLabs'
product line will be available for patients with a doctor's recommendation at
dispensaries throughout northern and southern California (for a full list of
dispensaries that carry LenitivLabs, please visit the LenitivLabs website) with
plans to expand to other states that allow for the sale of medical cannabis.
Note: Lenitiv Labs, LLC operates in
California as a non-profit mutual benefit corporation. All products are
manufactured in a licensed facility in strict compliance with local and state
laws. These statements have not been evaluated by the FDA and are not intended
to diagnose, treat, or cure any disease.
About Lenitiv
Scientific
Lenitiv Scientific develops
innovative, high quality medical cannabis products for patients. The company
works closely with regulators and provides education for the broader community
on topics such as proper dosage and methods of delivery. Lenitiv Scientific was
founded by Montel Williams and former pharmaceutical executive David Racz, who
serves as CEO. The company's world class advisory board includes Former
Director, Central Intelligence, Ambassador R. James Woolsey; Retired Vice
Admiral Edward M. Straw; former Congressman Wilbert Tauzin, former owner of
General Drug, Basil Falcone; Lindy Snider; and Nancye Miller-Woolsey.
This news is published on the
Investorideas.com Newswire - a global digital news source for investors and
business leaders
Disclaimer/Disclosure:Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
WeedMD Inc. (TSX VENTURE: $AMN.P) Announces
Closing of Qualifying Transaction
TORONTO, ONTARIO - April 19, 2017 (Investorideas.com Newswire)
WeedMD Inc. (TSX VENTURE:AMN.P) (formerly Aumento Capital V Corporation
("ACC")) (the "Company"), is pleased to announce that it
has closed its previously announced business combination (the "Transaction")
with WeedMD Rx Inc. ("RX"). The Transaction consisted of the
acquisition by the Company of all of the issued and outstanding securities in
the capital of RX by way of a three-cornered amalgamation, pursuant to which a
wholly-owned subsidiary of the Company amalgamated with RX.
Pursuant to the Transaction, each RX shareholder received 1.25
common shares in the capital of the Company for each RX common share held,
resulting in the issuance of an aggregate of 58,577,376 common shares of the
Company to shareholders of RX. As part of the Transaction, warrants,
compensation options and stock options of RX were replaced with common share
purchase warrants, compensation options and stock options of the Company with
adjustments to their exercise or conversion terms to reflect the exchange ratio
for the RX common shares under the Transaction, resulting in the issuance of:
(i) common share purchase warrants exercisable to purchase up to 14,888,486
common shares at an exercise price of $0.80 per share; (ii) stock options
exercisable to purchase up to 3,312,500 common shares at an exercise price of
$0.60 per share; and (iii) 440,000 compensation options exercisable into units
at an exercise price of $0.60 per unit, with each unit comprised of a common
share and one-half of one warrant, with each whole warrant exercisable into a
common share at an exercise price of $0.80.
As part of the Transaction, the Company changed its name from
"Aumento Capital V Corporation" to "WeedMD Inc.".
As a result of the Transaction, RX is now a wholly-owned
subsidiary of the Company, and the Company will continue the business of RX
which is licensed under the Access to Cannabis for Medical Purposes Regulations
to cultivate marijuana seeds and plants and dried marijuana product from its
facilities located in Aylmer, Ontario. RX has applied for an amendment to its
ACMPR license to allow for the sale of plants/dried materials (the "Sales
License"). RX has completed the review and inspection process with Health
Canada with respect to the Sales License. Upon RX satisfying any further
documentary or other requests of Health Canada, WeedMD expects to receive its
Sales License in the second quarter of 2017. There are no mandated timelines in
the ACMPR for the license review process.
Prior to the Transaction, ACC was a Capital Pool Company (as
defined under the policies of the TSX Venture Exchange (the
"Exchange")), and had not commenced commercial operations and had no
assets other than cash. The Transaction constituted ACC's "Qualifying
Transaction", as such term is defined in Policy 2.4 of the Exchange.
Final acceptance of the Transaction will occur upon the issuance
of a Final Exchange Bulletin by the Exchange. Upon issuance of the Final
Exchange Bulletin, the Company will cease to be a Capital Pool Company and will
recommence trading on the Exchange as a Tier 1 life sciences issuer. Trading in
the common shares of the Company will begin on the Exchange on April 27, 2017
under the symbol "WMD".
Following the completion of the Transaction (on a
post-acquisition basis), the Company has a total of 60,517,058 common shares
outstanding, as well as: (i) common share purchase warrants exercisable to
purchase up to 14,888,486 common shares at an exercise price of $0.80 per
share; (ii) stock options exercisable to purchase up to 3,497,332 common shares
at an exercise price of $0.60 per share; (iii) 440,000 compensation options
exercisable into units at an exercise price of $0.60 per unit, with each unit
comprised of a common share and one-half of one warrant, with each whole
warrant exercisable into a common share at an exercise price of $0.80; and (iv)
1,125,000 common shares issuable to certain officers of the Company upon RX
receiving the Sales License (the "Compensation Shares").
An aggregate of 23,388,441 common shares are subject to escrow
pursuant to Exchange escrow requirements (not including the Compensation Shares
which will also become subject to escrow upon issuance).
As a result of the closing of the Transaction, the directors and
executive officers of the Company are now:
Michael Kraft Chairman
Bruce Dawson-Scully Chief Executive Officer and Director
Keith Merker Chief Financial Officer and Director
Luc Duchesne Chief Scientific Officer
Gail Paech Director
David Danziger Director
Rick Moscone Director
Further details about the Transaction and the Company as the
resulting issuer from the Transaction are available in the filing statement of
ACC dated March 31, 2017 filed in respect of the Transaction which has been
filed under ACC's profile on SEDAR at www.sedar.com. The summary of the
Transaction set out herein is qualified in its entirety by reference to the
description of the Transaction in the filing statement.
Forward-Looking Information
This press release contains forward-looking information based on
current expectations. Statements about the date of trading of the Company's
common shares on the Exchange and final regulatory approvals, among others, are
forward-looking information. These statements should not be read as guarantees
of future performance or results. Such statements involve known and unknown
risks, uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those implied by
such statements. The Company assumes no responsibility to update or revise
forward-looking information to reflect new events or circumstances unless
required by law.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Contact
Information
Keith Merker
Chief Financial Officer
WeedMD Inc.
519-765-2440 Ext. 222
VANCOUVER, BC - April 19, 2017 (Investorideas.com Newswire)
Lotus Ventures Inc. (CNSX: J) is pleased to report that its activities to
obtain Licensed Producer (LP) status under the Health Canada, Access To
Cannabis For Medical Purposes Regulations (ACMPR) has moved forward and we are
poised to begin construction of the first facility in 2017.
Lotus has received approval for the necessary building permit
for its proto-type facility from Spallumcheen Township near Armstrong BC. We
have received a binding financial commitment to fund the two-stage
construction, previously announced on January 30, 2017 and have received
further information that Lotus Ventures Inc. has well advanced along in the
approval process and expects to receive an affirmation confirmation from Health
Canada to commence building this year. We have also created a community
contribution profile which highlights our creation of 60 - 70 permanent jobs
from the initial $18 million investment plan in the North Okanagan region.
Health Canada has increased its budget and staffing, which will
increase the speed at which it issues affirmation confirmations and processes
LP applications. The Federal Government has issued legislation in favor of LP's
being the permitted producers in the adult recreation legal market to commence
July 1, 2018.
These announcements are material milestones for Lotus Ventures
becoming an important market participant in the rapidly-developing Canadian
regulated market for both medical and adult recreational use markets. We anticipate
events developing more rapidly, in the near future, and will keep our
shareholders informed as we move forward with our business plans.
ON BEHALF OF THE BOARD
Lotus Ventures Inc.
Dale McClanaghan, President and CEO
The Canadian Securities Exchange does not accept responsibility
for the adequacy or accuracy of this release.